-
CD39: A Novel Target to Overcome Immunosuppression in Cancer(Post)
Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tu
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease(Post)Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
Microtubule and Mitosis review(Post)Introduction Microtubules are key components of the cytoskeleton and are composed of alpha and beta tubulin. These dimerise in a head to tail fashion to form 13 linear protofilaments.
Psychiatric disorders & LCN2(Post)By Ana Catarina Ferreira, PhD Candidate, Univeristy of Minho, Portugal Psychiatric disorders, including anxiety and depression, are highly prevalent conditio
Thymic T-Cell Development & Central Tolerance(Page) Monocytes: An Overview (Post)Monocytes, as part of the innate immune system, act as the first line of defense against foreign invaders. One of their primary functions is phagocytosis, a crucial process in which they engulf
Gut Inflammation and Inflammatory Diseases (Post)What is Gut Inflammation? The gut, or gastrointestinal (GI) tract is a long tube that starts from the mouth and extends to the anus. It includes various organs such
Cancer Research Club March 2020(Post)ELISA Genie is delighted to announce the date of our next Cancer Research Club which will be taking place on the 31st of March at TTMI, Trinity College Dublin. This event will focu
JAK-STAT Signalling and Cytokines: The What, How, and Why(Post)Cell Signalling · CytokinesJAK-STAT Signalling: Mechanism, Regulation and InhibitorsJAK-STAT is the shortest route from a cytokine outside the cell to a change in gene transcription — receptor engagem
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
ELISA Troubleshooting: When Standards Read Below the Blank(Post)Quick answer On the GDF-6 (Growth Differentiation Factor 6) ELISA Kit, a researcher saw an elevated blank (OD ≈ 0.41) with the two lowest standards reading at or below it, and no signa
Crizanlizumab: A Comprehensive Overview of Its Role in Sickle Cell Disease and Ongoing Research(Post)Quick Facts About CrizanlizumabWhat is Crizanlizumab?Crizanlizumab is a monoclonal antibody used to treat sickle cell disease by targeting P-selectin, a protein involved in inflammation
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr